Investigational drug · Phase 2
LY4005130
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV).
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "LY4005130"
First trial start
2026
Apr 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY4005130", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alopecia Areata
- Vitiligo
- Non-Segmental Vitiligo (NSV)
Approved drugs for the same conditions: Alopecia areata · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "LY4005130" as an intervention, largest first.
- A Study of LY4005130 in Healthy ParticipantsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06690996 · 110 participants · Start Nov 8, 2024 · Primary completion Apr 28, 2026
Drug: LY4005130; LY4005130 and 2 more · For: Healthy
Sites: Dallas, Texas
Eli Lilly and CompanyEli Lilly (LLY)
NCT07533019 · 66 participants (planned) · Start Apr 14, 2026 · Primary completion May 2027
Drug: LY4005130; Placebo · For: Vitiligo; Non-Segmental Vitiligo (NSV)
Sites: Phoenix, Arizona; Fremont, California; Northridge, California · 35 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07533006 · 65 participants (planned) · Start Apr 14, 2026 · Primary completion Jun 2027
Drug: LY4005130; Placebo · For: Alopecia Areata
Sites: Fremont, California; Northridge, California; Santa Clarita, California · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alopecia Areata
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials
Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata
- CTP-543Phase 31 trial
Sun Pharmaceutical Industries, Inc. · Alopecia Areata
- ADX-914bempikibartPhase 22 trials
Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata
- LAD603Phase 21 trial
Almirall, S.A. · Alopecia Areata
- NXC736Phase 21 trial
NEXTGEN Bioscience · Alopecia Areata
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.